{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T18:41:56Z","timestamp":1720550516602},"reference-count":20,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":274,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Exp Immunol"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1111\/cei.12538","type":"journal-article","created":{"date-parts":[[2014,12,29]],"date-time":"2014-12-29T12:43:26Z","timestamp":1419857006000},"page":"124-126","source":"Crossref","is-referenced-by-count":0,"special_numbering":"supplement S1","title":["7<sup>th<\/sup>International Immunoglobulin Conference: Interlaken Leadership Awards"],"prefix":"10.1093","volume":"178","author":[{"given":"M. C.","family":"Dalakas","sequence":"first","affiliation":[{"name":"University of Athens Medical School; Athens Greece"},{"name":"Thomas Jefferson University; Philadelphia PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. N.","family":"L\u00f6scher","sequence":"additional","affiliation":[{"name":"Innsbruck Medical University; Innsbruck Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2014,12,29]]},"reference":[{"key":"10.1111\/cei.12538-BIB0001|cei12538-cit-0001","unstructured":"CSL Behring Interlaken Leadership Awards Mission Statement 2014 http:\/\/www.interlakenleadershipawards.com\/about.aspx"},{"key":"10.1111\/cei.12538-BIB0002|cei12538-cit-0002","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1136\/jnnp.2003.034447","article-title":"Recommended diagnostic criteria for paraneoplastic neurological syndromes","volume":"75","author":"Graus","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1111\/cei.12538-BIB0003|cei12538-cit-0003","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/ana.410410615","article-title":"Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group","volume":"41","author":"Gajdos","year":"1997","journal-title":"Ann Neurol"},{"key":"10.1111\/cei.12538-BIB0004|cei12538-cit-0004","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/brain\/124.6.1138","article-title":"Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients","volume":"124","author":"Graus","year":"2001","journal-title":"Brain"},{"key":"10.1111\/cei.12538-BIB0005|cei12538-cit-0005","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1136\/jnnp.68.4.479","article-title":"Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone","volume":"68","author":"Keime-Guibert","year":"2000","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1111\/cei.12538-BIB0006|cei12538-cit-0006","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/archneurol.2012.595","article-title":"Cellular immune suppression in paraneoplastic neurologic syndromes targeting intracellular antigens","volume":"69","author":"Orange","year":"2012","journal-title":"Arch Neurol"},{"key":"10.1111\/cei.12538-BIB0007|cei12538-cit-0007","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1212\/WNL.55.5.713","article-title":"Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies","volume":"55","author":"Rojas","year":"2000","journal-title":"Neurology"},{"key":"10.1111\/cei.12538-BIB0008|cei12538-cit-0008","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s00415-005-0882-0","article-title":"An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes","volume":"253","author":"Shams'ili","year":"2006","journal-title":"J Neurol"},{"key":"10.1111\/cei.12538-BIB0009|cei12538-cit-0009","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1093\/brain\/awg133","article-title":"Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients","volume":"126","author":"Shams'ili","year":"2003","journal-title":"Brain"},{"key":"10.1111\/cei.12538-BIB0010|cei12538-cit-0010","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s00415-002-0706-4","article-title":"Survival and outcome in 73 anti-Hu positive patients with paraneoplastic encephalomyelitis\/sensory neuronopathy","volume":"249","author":"Sillevis Smitt","year":"2002","journal-title":"J Neurol"},{"key":"10.1111\/cei.12538-BIB0011|cei12538-cit-0011","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1136\/jnnp.60.4.388","article-title":"Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodies","volume":"60","author":"Uchuya","year":"1996","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1111\/cei.12538-BIB0012|cei12538-cit-0012","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1136\/jnnp.2009.177865","article-title":"Human chorionic gonadotropin treatment of anti-Hu-associated paraneoplastic neurological syndromes","volume":"81","author":"Broekhoven","year":"2010","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1111\/cei.12538-BIB0013|cei12538-cit-0013","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1215\/S1152851703000395","article-title":"Immunomodulatory treatment trial for paraneoplastic neurological disorders","volume":"6","author":"Vernino","year":"2004","journal-title":"Neuro Oncol"},{"key":"10.1111\/cei.12538-BIB0014|cei12538-cit-0014","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J Exp Med"},{"key":"10.1111\/cei.12538-BIB0015|cei12538-cit-0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pediatrneurol.2006.09.016","article-title":"Pathophysiology of Duchenne muscular dystrophy: current hypotheses","volume":"36","author":"Deconinck","year":"2007","journal-title":"Pediatr Neurol"},{"key":"10.1111\/cei.12538-BIB0016|cei12538-cit-0016","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2147\/NDT.S8915","article-title":"Current and emerging therapies for the treatment of myasthenia gravis","volume":"7","author":"Mantegazza","year":"2011","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1111\/cei.12538-BIB0017|cei12538-cit-0017","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/qjmed\/hcn152","article-title":"Myasthenic crisis","volume":"102","author":"Chaudhuri","year":"2009","journal-title":"Q J Med"},{"key":"10.1111\/cei.12538-BIB0018|cei12538-cit-0018","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jneuroim.2005.01.018","article-title":"Immune responses to Campylobacter and serum autoantibodies in patients withcomplex regional pain syndrome","volume":"162","author":"Goebel","year":"2005","journal-title":"J Neuroimmunol"},{"key":"10.1111\/cei.12538-BIB0019|cei12538-cit-0019","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1016\/j.pain.2011.06.012","article-title":"Autoimmunity against the beta(2) adrenergic receptor and muscarinic-2 receptor in complex regional pain syndrome","volume":"152","author":"Kohr","year":"2011","journal-title":"Pain"},{"key":"10.1111\/cei.12538-BIB0020|cei12538-cit-0020","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.pain.2013.10.011","article-title":"A CRPS-IgG-transfer-trauma model reproducing inflammatory and positive sensory signs associated with complex regional pain syndrome","volume":"155","author":"Tekus","year":"2014","journal-title":"Pain"}],"container-title":["Clinical &amp; Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcei.12538","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/cei.12538\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T16:27:27Z","timestamp":1641054447000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cei.12538"}},"subtitle":["Interlaken Leadership Awards"],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":20,"URL":"https:\/\/doi.org\/10.1111\/cei.12538","archive":["Portico"],"relation":{},"ISSN":["0009-9104"],"issn-type":[{"value":"0009-9104","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]}}}